l e t t e r s Using the Immunochip custom SNP array, which was designed for dense genotyping of 186 loci identified through genome-wide association studies (GWAS), we analyzed 11,475 individuals with rheumatoid arthritis (cases) of European ancestry and 15,870 controls for 129,464 markers. We combined these data in a meta-analysis with GWAS data from additional independent cases (n = 2,363) and controls (n = 17,872). We identified 14 new susceptibility loci, 9 of which were associated with rheumatoid arthritis overall and five of which were specifically associated with disease that was positive for anticitrullinated peptide antibodies, bringing the number of confirmed rheumatoid arthritis risk loci in individuals of European ancestry to 46. We refined the peak of association to a single gene for 19 loci, identified secondary independent effects at 6 loci and identified association to low-frequency variants at 4 loci. Bioinformatic analyses generated strong hypotheses for the causal SNP at seven loci. This study illustrates the advantages of dense SNP mapping analysis to inform subsequent functional investigations.
Rheumatoid arthritis is a common, complex disease affecting up to 1% of the adult population. It is an archetypal autoimmune disease typified by the presence of serum autoantibodies, including antibodies directed against the Fc portion of immunoglobulins (rheumatoid factor) and against citrullinated peptides (anticitrullinated peptide antibodies (ACPAs)). Genetic studies of rheumatoid arthritis, including the recent application of GWAS, have identified 32 risk loci among individuals of European ancestry, including HLA-DRB1, PTPN22 and other loci with shared autoimmune associations 1, 2 .
The Immunochip consortium was formed to design a custom Illumina Infinium array that leveraged the remarkable genetic overlap of susceptibility loci identified across a range of autoimmune diseases. The custom array allows investigators to perform gene-discovery and fine-mapping experiments in a coordinated manner. Full details of this array have been described previously 3 . Briefly, it consists of all known SNPs from the 1000 Genomes Project as well as private resequencing efforts for 186 loci known to be involved in any of 12 autoimmune diseases. For these loci, there is the unique opportunity to fine map associations to autoimmune diseases. Additional SNPs were included as part of a deep replication effort. This provided the opportunity not only to identify new rheumatoid arthritis associations with loci implicated in other autoimmune diseases or with variants showing suggestive statistical evidence for association from a previous metaanalysis but also to refine the GWAS signal and reduce the number of potential causal variants in the 31 confirmed non-HLA loci.
We tested 129,464 polymorphic markers passing quality control with a minor allele frequency (MAF) >1% in 11,475 cases (7, 222 ACPA positive, 3,297 ACPA negative and 957 unassigned) and 15,870 controls ( Table 1 and Supplementary Tables 1 and 2) . We performed an analysis on the total rheumatoid arthritis dataset and also on subsets stratified by ACPA status ( Supplementary Table 3 ). We also had access to GWAS data for an additional 2,363 ACPA-positive cases and 17,872 controls that were independent of the current study ( Table 1) . We found strong evidence of association for the previously identified susceptibility loci ( Table 2 and Supplementary Tables 3 and 4) .
We identified 14 new rheumatoid arthritis loci for populations of European ancestry (TYK2, IRAK1, TLE3, RASGRP1, PADI4, IL6R, IRF8, ARID5B, IKZF3, RUNX1, POU3F1, RCAN1, CD5 and GATA3) at genome-wide levels of significance (P < 5 × 10 −8 ) ( Fig. 1) , 7 with High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis l e t t e r s Immunochip data alone ( Table 2 ) and a further 7 when Immunochip data were combined with the GWAS meta-analysis data ( Table 2) . These loci add 4% to the estimate of heritability explained by confirmed loci, bringing the total to 51%, of which HLA explains 36%. When we removed all known loci from the Immunochip data, we still observed evidence of an excessive number of nominally associated alleles, which is consistent with the possibility that there are many additional undiscovered alleles 4 (Supplementary Fig. 1) . Notably, when we applied a study-wide significance threshold of P < 9.0 × 10 −7 (calculated on the basis of the number of effective independent tests when accounting for linkage disequilibrium (LD)), we also found a significant association at two additional loci: ELMO1 (rs75351767, P all = 2.94 × 10 −7 ) and BACH2 (rs72928038, P all = 8.23 × 10 −7 ) (Supplementary Table 3 ). A further eight loci were implicated at suggestive levels of significance (P < 1 × 10 −5 ) in either the full or the ACPA-positive subgroup analysis, including PTPN2 (rs62097857, P all = 4.4 × 10 −6 ), TNIP1 (rs6579837, P pos = 1.7 × 10 −6 ) and TNFSF4 (rs61828284, P pos = 5.4 × 10 −6 ) ( Supplementary Table 3 ).
Previously, we fine mapped MHC associations observed in GWAS data of partially overlapping samples by applying imputation of HLA classical alleles and amino acids 5 . The Immunochip platform includes denser SNP coverage within the MHC region, which facilitates more accurate imputation. In a preliminary analysis applying the same imputation and fine-mapping approach to ACPA-positive cases and controls typed on Immunochip, we observed the same associations that we reported previously. The most significant polymorphic nucleotide was again rs17878703, mapping to position 11 of the HLA-DRB1 peptide sequence (P < 10 −677 ). Testing individual amino acid positions within HLA-DRB1 revealed the strongest association to be at position 11 (P < 10 −745 ). Conditioning on the position 11 effect, we observed an association at position 71 (P = 6 × 10 −60 ). Finally, conditioning on effects at both positions 11 and 71, we observed a significant association at position 74 (P = 7 × 10 −19 ). Adjusting for all HLA-DRB1 alleles to identify independent effects outside this gene, we observed significant associations at HLA-B corresponding to the presence of aspartate at position 9 in the peptide sequence (P = 1 × 10 −17 ). Adjusting for all HLA-DRB1 alleles and Asp9 in HLA-B, we observed associations at HLA-DPB1 corresponding to the presence of phenylalanine at position 9 in the peptide sequence (P = 1 × 10 −17 ).
Although it has been demonstrated that ACPA-positive disease and ACPA-negative disease have different allelic associations at the MHC and at PTPN22 (ref. 6 ), previous studies have not been sufficiently powered to address this issue definitively in additional non-MHC loci. Here we analyzed 3,297 ACPA-negative cases and identified association at genomewide significance to ANKRD55 (rs71624119, P = 5.2 × 10 −12 , odds ratio (OR) = 0.78) in addition to HLA (rs4143332, P = 2.9 ×10 −15 , OR = 1.37) (Supplementary Table 3 ). Notably, ANKRD55 has a similar effect in ACPA-negative as in ACPA-positive disease. Comparing the associations in the ACPA-positive and ACPA-negative subgroups, we observed that for the 45 non-HLA loci, around half showed a significantly larger effect size in ACPA-positive disease (P < 0.05 for the comparison of the ORs), with 5 of these loci having a markedly stronger association with this form of disease (PTPN22, CCR6, CD40, RASGRP1 and TAGAP). Eleven loci showed no statistical difference in association to either form of rheumatoid arthritis (Supplementary Table 5 ). This preliminary analysis indicates that differences in the serological subtype of disease may be reflected in a difference in genetic predisposition, potentially providing a basis for stratified medicine.
We found that the majority of the 14 loci newly associated with rheumatoid arthritis susceptibility, along with the previously confirmed loci, contain genes that are strongly linked to immune function using GRAIL analysis (Supplementary Table 6 and Supplementary  Fig. 2 ), for example, CD5, IRF8 and TYK2. We also report a new association with IRAK1, which has previously been associated with systemic lupus erythematosus 7 . This is the first association of the X chromosome locus with rheumatoid arthritis and is of relevance given the female predominance of both diseases (9:1 and 3:1 ratios of females to males in systemic lupus erythematosus and rheumatoid arthritis, respectively). Interestingly, this locus has been shown to occasionally escape X inactivation in female cells 8 . Three of the new loci confirmed here in samples of European ancestry have been previously associated with rheumatoid arthritis in either samples of east Asian ancestry (PADI4 and ARID5B) or when using a multiethnic approach (IKZF3) [9] [10] [11] . The SNPs associated in this study are moderately correlated with those identified in samples of east Asian origin (PADI4 SNPs rs2240336 and rs766449, r 2 = 0.25, D′ = 1; ARID5B SNPs rs12764378 and rs10821944, r 2 = 0.52, D′ = 0.86). PADI genes are involved in the citrullination of peptides and, as such, are strong candidates for involvement in disease given the presence of ACPA autoantibodies. Although the association at PADI4 (rs2240336) is greater in ACPA-positive (OR = 0.88, P = 6.49 × 10 −9 ) compared to ACPA-negative cases (OR = 0.93, P = 0.01), our formal test comparing the ORs between these subgroups did not show a statistically significant difference (P = 0.14).
We applied conditional logistic regression to test for secondary effects within each locus. In six non-HLA loci (13%) (TNFAIP3, CD28, REL, STAT4, TYK2 and RASGRP1), we found additional independent association signals ( Supplementary Fig. 3 ). In total, we observed 51 independent risk alleles in 45 non-HLA rheumatoid arthritis loci. To test the possibility that the two risk alleles tag an untyped SNP, npg l e t t e r s l e t t e r s we carried out a haplotype analysis of the six loci but found no evidence for haplotype-specific effects at any locus ( Supplementary  Table 7 ). At only four loci (REL, CD28, TYK2 and TNFAIP3) did we observe associations with low-frequency variants (MAF < 0.05) (Supplementary Table 8 ).
Out of the 46 rheumatoid arthritis susceptibility loci, 39 were densely genotyped by Immunochip. For 12 loci, we observed that the most strongly associated SNP was not tightly linked to the previously reported lead SNP at that locus, shifting the association signal ( Supplementary Table 9 ). For the 39 confirmed non-HLA rheumatoid arthritis loci on Immunochip, dense mapping refined the association to a single gene for 19 loci ( Supplementary Table 10 ).
Our analysis also identified seven nonsynonymous SNPs within exonic regions ( Table 3) , as well as a number showing strong regulatory potential (Supplementary Table 11) , that are highly correlated (r 2 > 0.9) with the lead SNP and are strong candidates for the etiological variant. The most strongly associated SNP at the IL6R locus (rs8192284) is nonsynonymous, shows high correlation with circulating IL-6R concentrations and, as well as being associated with a decrease risk of coronary heart disease 12, 13 , is in strong LD (r 2 = 0.97, D′ = 1) with a SNP recently reported to be associated with asthma (rs4129267) 14 . Notably, the risk allele at the asthma-associated SNP (OR = 1.09, P = 2.4 × 10 −8 ) is protective for rheumatoid arthritis (OR = 0.9, P = 1.3 × 10 −8 ). IL-6R is the target of the biologic drug tocilizumab, which has been shown to be an effective treatment for rheumatoid arthritis. Abatacept is another biologic drug with therapeutic efficacy in clinical trials that targets another rheumatoid arthritis susceptibility gene, CTLA4. These examples highlight the potential for targeting genes within risk loci.
Testing for statistical interactions between the 46 lead SNPs in confirmed rheumatoid arthritis loci identified preliminary evidence for six significant pairwise interactions after Bonferroni correction (P < 5 × 10 −4 ) (Supplementary Table 12) . The GATA3-PRKCQ interaction is supported by earlier biological observations 15 .
Among 38 rheumatoid arthritis-associated SNPs or proxies accessed for expression quantitative trait loci (eQTL) analysis, 18 showed an eQTL effect on at least one probe, giving a total of 51 SNPprobe combinations with a significant eQTL effect ( Supplementary  Table 13 ). Among these 18 SNPs, 11 showed an independent or primary eQTL effect on one or more probes (20 SNP-probe combinations), whereas seven SNPs were not significant after conditioning the strongest eQTL signal in the locus.
Using a previously described approach, we assessed whether the 46 independent rheumatoid arthritis-associated regions, defined by previously known and newly discovered SNP associations, harbored genes that were specifically expressed in distinct immune cell types 16 . We found in a large expression dataset of 223 sorted mouse immune cells 17 that these regions contained genes that were most significantly more specifically expressed in CD4 + effector memory T-cell subsets (P < 10 −7 ) (Supplementary Fig. 4) .
Of the diseases sharing susceptibility loci with rheumatoid arthritis, systematic fine mapping has only been published so far for celiac disease 3 . Previously, the two diseases were found to share six confirmed non-HLA loci (MMEL, REL, CD28-CTLA4, TNFAIP3, TAGAP and IL2-IL21) 2 . Immunochip data now identifies an additional four confirmed loci common to both diseases (DDX6, STAT4, PRKCQ and IRAK1) and a further four potential rheumatoid arthritis loci (BACH2, P = 8.2 × 10 −7 ; ELMO1, P = 2.9 × 10 −7 ; PTPN2, P = 4.4 × 10 −6 ; and PVT1, P = 2 × 10 −5 ) in common with confirmed celiac disease loci ( Supplementary  Table 14 ). Of the ten shared rheumatoid arthritis and celiac disease loci, four have the same lead SNP (CD28, IL2-IL21, TNFAIP3 and IRAK1) and a fifth (MMEL1) shares highly correlated SNPs (r 2 > 0.88), and for all of these variants, the risk allele is the same for both diseases. For two loci (PRKCQ and DDX6), the lead SNPs are only moderately correlated (r 2 > 0.62), with the minor allele being protective in both diseases. The effects in STAT4 seem quite different, with three independent effects in celiac disease and two different independent associations in rheumatoid Chr1 P < 10 -100 MMEL1-TNFRSF14  PADI4  POU3F1  PTPN22  IL6R*  REL  SPRED2  AFF3  STAT4  CD28-CTLA4  RBPJ   ANKRD55  C5orf30*  MHC  TNFAIP3  TAGAP  CCR6   CCL21  TRAF1  IL2RA  GATA3  ARID5B  CD5*  DDX6   RASGRP1  TLE3  IRF8  IKZF3  TYK2  CD40 npg arthritis. The strongest association signal for risk of celiac disease at TAGAP is with the minor allele of a SNP (rs182429) in moderate LD (r 2 = 0.44) with the rheumatoid arthritis risk SNP (rs629326). Indeed, when considering overlap of rheumatoid arthritis susceptibility loci with those of other autoimmune diseases, only the PADI4 and CCL21 non-MHC loci show unique association, suggesting that they may be important in determining that the autoimmune reaction is directed at synovial joints. In summary, through fine mapping on a custom-made array designed to capture variation across a number of loci associated with autoimmune diseases, we have identified 14 new rheumatoid arthritis susceptibility loci in individuals of European ancestry, refined the peak of association to a single gene at 19 loci, identified 7 SNPs that might potentially be functional, found independent effects at 6 loci and detected association with SNPs with low MAF (<0.05) at four loci. In one-third of cases, imputation of GWAS signals without fine mapping would have implicated a different genetic region as being causal, thus illustrating the importance of dense fine-mapping analysis before embarking on intensive functional studies.
METhodS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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Interaction analysis.
We performed an analysis of epistasis using the most significantly associated SNP from each of the 46 loci ( Table 2) . Logistic regression was performed in PLINK to model epistasis in each of the six datasets with the top ten principal components included as covariates. For each pair of SNPs, the likelihood ratio test was used to compute the P value of the interaction term for each dataset. Epistasis results were combined using METAL and were Bonferroni corrected. eQTL analysis. eQTL analysis was done on the peripheral blood of 1,469 unrelated individuals (1,240 samples run on the Illumina HT12v3 platform and 229 samples run on the Illumina H8v2 platform) from the UK and The Netherlands. Details of the eQTL analysis have been previously described 22 .
In short, we assessed the effect of all rheumatoid arthritis-associated SNPs (Table 2) on the expression of genes located within 250 kb to the left and right of the SNP (cis eQTLs).
All individuals from the eQTL study were genotyped on the Illumina Hap300K platform and then imputed to HapMap 2 using Impute 2.0 software. Because not all SNPs from the Illumina Immunochip platform were genotyped or imputed on the 1,469 eQTL samples, we used the following strategy ( Supplementary Fig. 5 ). First, we investigated whether the SNP is present in the eQTL data and passed the quality control for eQTL mapping (MAF ≥ 5%, P HWE ≥ 0.001, call rate ≥ 95%). From 50 rheumatoid arthritis SNPs, 26 were present in HapMap-imputed datasets and were directly assessed for eQTL effects ( Supplementary Table 13 ). For the other 24 SNPs not present in our HapMap imputed data, we checked whether the rheumatoid arthritis SNP was available in the 1000 Genomes database. If so, we queried all SNPs within 10 Mb of the rheumatoid arthritis SNP that were also present in the eQTL data and would pass the eQTL quality control measures and picked the SNP with the highest LD that was present in HapMap after quality control.
The threshold of r 2 > 0.8 for the LD was used. For 12 SNPs, no proxy was available using our criteria, and these SNPs were not included in the eQTL analysis. For the remaining 12 SNPs, the best proxy SNP is included in the eQTL table (Supplementary Fig. 5) .
We also performed a cis-eQTL analysis for the top associated gene expression probe, as well as two conditional analyses, one conditioning on the effect of the rheumatoid arthritis SNP (gSNP) and one conditioning on the effect of the top eQTL SNP (eSNP) (Supplementary Table 13) .
The rheumatoid arthritis-associated SNP was labeled as having a primary effect on gene expression if it was either the top eQTL in the locus or was a good proxy for the top eQTL SNP (r 2 > 8). It was labeled as an independent eQTL if it showed an effect after conditioning on the primary eQTL. From 20 rheumatoid arthritis SNPs that showed an eQTL effect, 13 had either an independent or primary eQTL effect on one or more probes (22 SNP-probe combinations). A further seven SNPs were not significant after the conditioning of the strongest eQTL signal in the locus, suggesting that they are not primary eQTLs.
